Attralus Announces First Subject Enrolled in Phase I Clinical Trial of AT-02, Its Lead Pan-Amyloid Removal Therapeutic Candidate

Attralus, Inc. announced that the first subject has been dosed in the Phase I clinical trial of AT-02, the company’s lead pan-amyloid removal therapeutic. The clinical trial is enrolling both healthy volunteers and patients with systemic amyloidosis.